Northwestern Mutual Wealth Management Co. Lowers Position in Pfizer Inc. $PFE

Northwestern Mutual Wealth Management Co. lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 11.2% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 514,459 shares of the biopharmaceutical company’s stock after selling 64,703 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Pfizer were worth $12,388,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. BlackRock Inc. raised its position in shares of Pfizer by 6.3% during the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after purchasing an additional 31,412,883 shares during the period. State Street Corp boosted its holdings in Pfizer by 0.5% in the 4th quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock worth $7,481,085,000 after buying an additional 1,357,756 shares during the period. Geode Capital Management LLC increased its stake in Pfizer by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock worth $3,235,642,000 after buying an additional 1,184,728 shares in the last quarter. Morgan Stanley increased its stake in Pfizer by 19.2% in the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after buying an additional 14,342,946 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Pfizer during the fourth quarter worth about $1,830,986,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Monday, July 6th. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a report on Tuesday, June 9th. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. HSBC lowered shares of Pfizer from a “buy” rating to a “hold” rating and dropped their target price for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Finally, Weiss Ratings cut shares of Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, August 17th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $28.28.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $27.97 on Tuesday. Pfizer Inc. has a 52 week low of $23.58 and a 52 week high of $28.75. The stock has a market capitalization of $159.41 billion, a P/E ratio of 36.80 and a beta of 0.34. The firm has a fifty day simple moving average of $25.34 and a two-hundred day simple moving average of $26.26. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the prior year, the company earned $0.78 EPS. The business’s revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. Pfizer’s dividend payout ratio is 226.32%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.